Press Release
China Medical System (867.HK; 8A8.SG) Signed Collaboration Agreements for Two Innovative Biologics Used for Passive Immunization Against Tetanus and Rabies
China Medical System (867.HK; 8A8.SG) Signed Collaboration Agreements for Two Innovative Biologics Used for Passive Immunization Against Tetanus and Rabies
SHENZHEN, CHINA – China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that on 22 September 2025, the Group through its subsidiaries entered into two separate exclusive Collaboration Agreements (the “Agreements”) with Chongqing Genrix Biopharmaceutical Co., Ltd. (“Genrix Bio”) for two Class 1 therapeutic biological products, Vecantoxatug Injection (GR2001, “Vecantoxatug”) indicated for passive immunization against tetanus and Silevimig Injection (GR1801, “Silevimig”) indicated for passive immunization following suspected rabies virus exposure, respectively. In accordance with the Agreements, the Group has obtained exclusive commercialization rights for these two products in mainland China and exclusive licensing rights for the rest of the Asia-Pacific region, the Middle East and North Africa. The collaboration terms respectively extend until ten years after these two products receive their marketing approvals in Mainland China (the “Initial Term for each Product”). Unless terminated or dissolved under the terms set forth in the Agreements, the Agreements will automatically renew for successive ten-year periods upon expiration of the Initial Term for each Product.
Vecantoxatug is a passive immunization agent with an excellent safety profile, which delivers superior protection compared with human tetanus immunoglobulin (HTIG), providing rapid and durable immune defense for patients. Its Phase III clinical trial for passive immunization against tetanus successfully met the primary efficacy endpoint. In May 2024, Vecantoxatug was designated Breakthrough Therapy by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). On 22 May 2025, its New Drug Application (NDA) was formally accepted by the CDE.
Silevimig is the world’s first recombinant, fully human bispecific antibody against rabies virus (RABV) targeting epitope I and/or epitope III of the rabies virus glycoprotein, developed in accordance with the World Health Organization (WHO) recommended “cocktail” therapeutic option targeting distinct antigenic sites. It can be manufactured at scale with standardized, and also demonstrates broad neutralization, low immunogenicity, minimal interference with vaccine-induced active immunity, and controlled production cost. On 14 January 2025, its NDA for use in adults requiring passive immunization following suspected rabies virus exposure was formally accepted by CDE. In addition, in July 2025, the NMPA approved the clinical trial application for Silevimig in children and adolescents aged 2 to <18 years requiring passive immunization following suspected rabies virus exposure. This Phase III clinical trial is currently in progress.
CMS has always been committed to deploying innovative products with clinical value and differentiated advantages. The market for tetanus and rabies passive immunization remains substantial, yet existing passive immunization products are constrained by safety and accessibility concerns. If approved, Vecantoxatug and Silevimig will provide new preventive and therapeutic options of passive immunization for patients following tetanus and rabies exposure. Additionally, they will synergize with the Group’s existing products in expert networks and market resources, bringing benefit to patients.
More information about Vecantoxatug and Tetanus
Vecantoxatug is a recombinant humanized monoclonal antibody against tetanus neurotoxin (TeNT), which is self-developed by Genrix Bio. Vecantoxatug binds to the fragment C domain of the TeNT heavy chain (TeNT-Hc). TeNT is an about 150 kDa single-chain protein that undergoes post-translational modification to form an active toxin composed of heavy and light chains. By specifically binding TeNT-Hc, Vecantoxatug effectively blocks toxin entry into neurons, providing passive immunization. The patent for Vecantoxatug has been granted in China.
Tetanus is an acute and specifical infection caused by Clostridium tetani (C. tetani) entering the body through wounds. It affects individuals across all age groups and, in the absence of medical intervention, is almost universally fatal-particularly among infants and the elderly. Even with active treatment, global mortality remains as high as 30-50%, with an estimated 500,000 to 1,000,000 cases reported annually worldwide[1].
C. tetani is ubiquitous in soil and the environment, and is also present in the intestines of mammals. As the pathogen invades through skin or mucosal injuries, causing the acute and specifical infection, prevention remains the most effective strategy. Currently available passive immunization agents, commonly known as tetanus shot, – tetanus antitoxin (TAT), equine-derived tetanus immunoglobulin (F(ab’)₂), and human tetanus immunoglobulin (HTIG) – face notable limitations in safety and accessibility[2], including risks of allergic reactions, potential infectious pathogen transmission, and limited availability. Consequently, there remains a pressing clinical need for new preventive and therapeutic options. Vecantoxatug is able to provide greater protection than HTIG, while demonstrating excellent safety, tolerability, and low immunogenicity. With enhanced controllability and accessibility, Vecantoxatug has the potential to offer patients an advanced preventive and therapeutic option.
More information about Silevimig and Rabies
Silevimig is a recombinant, fully human bispecific antibody against rabies virus, which is self-developed by Genrix Bio. It targets the viral envelope glycoprotein (G protein) of RABV and blocks its interaction with host receptors by binding to epitopes I and/or III. Through this mechanism, Silevimig prevents RABV from invading neural tissue prior to the establishment of full protection by active rabies vaccination, thereby helping to prevent rabies infection. Silevimig’s molecular design is consistent with the recommendations of the WHO for anti-RABV antibody development, which emphasize the use of “cocktail” combinations of monoclonal antibodies targeting distinct antigenic sites to ensure broad effectiveness across different viral strains and genotypes. The patent for Silevimig has been granted in China.
In a Phase III clinical trial for post-exposure passive immunization in adults, Silevimig met its primary efficacy endpoint, demonstrating non-inferior protective efficacy compared with human rabies immunoglobulin (HRIG), the currently most used passive immunization product in China. The study confirmed that Silevimig provides immediate protection during the early stages of rabies virus exposure without compromising the active immune response induced by vaccination.
Rabies is an acute zoonotic disease caused by RABV, clinically characterized by hydrophobia, aerophobia, pharyngeal muscle spasms, and progressive paralysis[3]. With a case-fatality rate approaching 100%, it is one of the deadliest diseases worldwide. At present, there is no proven treatment for rabies once clinical symptoms appear. Standardized Post-Exposure Prophylaxis (PEP), comprising wound care, vaccination, and passive immunization administered as needed, remains the most effective rabies prevention strategy[4]. As vaccine-induced antibodies require 1–2 weeks after the first dose of vaccine injection, to reach protective levels (≥0.5 IU/mL), passive immunization provides immediate coverage during this high-risk window[3]. According to the the National Regulation for the Rabies Exposure Prophylaxis (2023 Edition), patients with Category III exposure and those with severe immunodeficiency and Category II exposure should receive passive immunization at the same time as the first dose of rabies vaccine[5]. In China, more than 40 million people are exposed to rabies annually, of whom approximately 40% (16 million) fall under Category III exposure[3]. However, due to factors such as limited awareness, high cost, and restricted accessibility, only about 15% of Category III cases receive passive immunization[3].
Currently approved passive immunization options in China include human rabies immunoglobulin (HRIG) and equine rabies antiserum (ERA), both of which provide immediate protection by preventing viral entry into neural tissue. HRIG must be sourced from repeatedly immunized healthy donors, making it difficult and costly to obtain. And it is associated with potential risks of blood-borne infections (e.g., HIV, hepatitis B, hepatitis C). ERA, being a heterologous protein, is prone to adverse reactions such as serum sickness and anaphylactic shock[3]. Beyond HRIG and ERA, only two rabies antibody products have been approved in China to date. Silevimig is the world’s first recombinant, fully human bispecific antibody for passive immunization against rabies, which is consistent with the WHO recommended “cocktail” approach. Its approval is expected to provide patients with broad and robust protection.
About GENRIX BIO
Genrix Bio (Stock Code: 688443), founded in 2015, is an innovative biopharmaceutical company driven by advanced antibody drug discovery technology to address critical clinical needs. Genrix Bio is committed to the development of monoclonal and bispecific antibodies for autoimmune diseases, infectious diseases, and oncology. Its capabilities span across antibody molecular discovery, process development and quality research, clinical trials, and large-scale commercialization. Learn more about Genrix Bio and its products at https://www.genrixbio.com/
About CMS
CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.
CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.
CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries, strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology/ophthalmology/ skin health businesses. Among them, the skin health business has become a leading enterprise in its field, bringing economies of scale in specialty therapeutic fields. Meanwhile, CMS continuously deepens its business development in the Southeast Asia and Middle East regions, further escorting the sustainable and healthy development.
Reference:
- China Trauma Rescue and Treatment Association. Peking University Trauma Medicine Center. Chinese expert consensus on tetanus immunization[J]. Chinese Journal of Surgery,2018,56(3):161-167. DOI: 10.3760/cma.j.issn.0529-5815.2018.03.001
- Members of the Emergency Surgery Committee of Chinese College of Emergency Physicians, Members of the Emergency Medicine Committee of the People’s Liberation Army, Beijing Society for Emergency Medicine, et al. Expert consensus on prophylaxis, diagnosis and management of tetanus among adults[J]. Journal of Clinical Emergency, 2018, 19(12):801-811. DOI: 10.13201/j.issn.1009-5918.2018.12.001
- Chinese Center for Disease Control and Prevention. Technical Guidelines for Human Rabies Prevention and Control (2016). https://www.chinacdc.cn/jkyj/crb2/yl/kqb/jswj_kqb/202409/P02024090652542…
- Yin Wenwu, Wang Chuanlin, et al. Expert consensus on rabies exposure prophylaxis[J]. Chinese Journal of Preventive Medicine, 2019,53(7):668-679. DOI:10.3760/cma.j.issn.0253-9624.2019.07.004
- Chinese Center for Disease Control and Prevention. The National Regulation for the Rabies Exposure Prophylaxis (2023 Edition). https://www.chinacdc.cn/jkyj/crb2/yl/kqb/jswj_kqb/202409/P02024090652542…
CMS Disclaimer and Forward-Looking Statements
This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.
This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.
Media Contact
Brand: China Medical System Holdings Ltd.
Contact: CMS Investor Relations
Email: ir@cms.net.cn
Website: https://web.cms.net.cn/en/home/
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
NANOGEIOS Develops Revolutionary IRIS X Platform for Cost Effective Natural Hydrogen and Helium Detection
NANOGEIOS and AIDEN DIGITAL LABS have developed the IRIS-X platform, a breakthrough technology that reduces the cost of natural hydrogen exploration by 95-98% and cuts deployment time from 18 months to 8 weeks, enabling rapid and sustainable resource discovery.
A breakthrough in sustainable resource exploration technology
MIAMI, FL — September 18, 2025 — Growing global demand for clean energy and accelerating climate change mitigation efforts have intensified the search for sustainable alternatives. Natural hydrogen emerges as a promising zero-carbon energy solution due to its high energy density and clean combustion characteristics. Among exploration methods, conventional drilling and seismic surveying remain costly and inefficient; however, their dependence on extensive surface disturbance and multi-million dollar budgets limits large-scale implementation. Advanced subsurface detection offers a practical alternative by leveraging Earth’s natural hydrogen and helium resources, but high operational costs, extended timelines, and environmental impacts pose significant challenges for sustainable resource development.
To address this, a research team led by Abdelmoumen Shad Serroune at NANOGEIOS Laboratory, in partnership with AIDEN DIGITAL LABS, developed a robust and cost-effective exploration platform capable of high-performance resource detection in complex geological environments. Dr. Serroune shares the motivation behind this breakthrough: “Conventional exploration methodologies, though established within the industry, face significant challenges including prohibitive costs, extended deployment periods, and environmental concerns that hinder commercialization. Our research is driven by the mission to develop economically viable and environmentally sustainable resource exploration technology to overcome these critical barriers.” Their findings were first published in the International Journal of Medical Science and Clinical Invention in July 2025.
The team designed the IRIS-X (Integrated Reconnaissance and Imaging System – eXtended) an exploration platform that overcomes limitations of conventional drilling and seismic methods in natural hydrogen and helium exploration with the unique ability to be adapted for rare earth minerals, noble gases and minerals. They employed proprietary nano biomarker technology combined with advanced metal-oxide semiconductor (MOS) sensor arrays to synthesize selective detection matrices with crystalline-amorphous heterostructures. The nano-biomarkers are engineered to latch onto target molecules like hydrogen and helium with remarkable precision, achieving near-perfect binding efficiencies of 99.1% and 98.4%, respectively. During deployment, controlled nitrogen carrier injection facilitates uniform subsurface distribution while real-time magnetic tracking systems provide three-dimensional pathway reconstruction capabilities.
Comprehensive field testing in Indonesia’s Padang region demonstrated outstanding resource detection performance. Over a 14-week validation campaign, IRIS-X exhibited exceptional analytical capabilities with 92% detection efficacy across variable lithological settings.
The platform successfully quantified hydrogen accumulations totaling 18.5±2.3 million cubic meters while maintaining measurement precision within ±5% variance across challenging tropical conditions. Durability was confirmed through sustained operation across diverse geological formations including serpentinization zones and radiolysis environments. Crucially, the platform demonstrated exceptional cost-effectiveness with operational expenditures of $1,500,000 per campaign compared to conventional methods requiring $5-20 million, representing a 95-98% cost reduction while compressing deployment timelines from 6-18 months to 6-8 weeks.
The study highlights several distinct advantages. The IRIS-X platform synergistically combines high-sensitivity detection with optimized operational efficiency through radial well configurations covering 20,000 square meters per deployment with the ability to reach 100.000 sqm. The integrated AI-driven data processing prevents measurement artifacts while enabling real-time resource quantification. The overall design provides exceptional environmental stewardship with zero operational incidents and minimal surface disturbance. Together, these features enable cost-effective, scalable resource exploration directly from natural formations while reducing environmental impact and supporting decarbonization across energy-intensive sectors.
AMS Serroune emphasizes, “Our breakthrough enables direct natural hydrogen and helium exploration from subsurface formations using advanced nano biomarker technology, opening vast geological resources for clean energy generation.” He adds, “The enhanced exploration systems demonstrate remarkable economic viability with 95-98% cost reduction compared to conventional methods, making resource discovery significantly more accessible for commercial development.“.
Looking toward future applications, the IRIS-X architecture supports expansion into critical mineral exploration through aptamer-functionalized nano biomarker systems specifically engineered for uranium, thorium, lithium, cobalt, and rare earth element detection, positioning the technology at the forefront of the global energy transition.
In conclusion, this work establishes a nano biomarker-mediated detection strategy that simultaneously addresses sensitivity, efficiency, and environmental challenges in subsurface resource exploration. Dr. Serroune notes, “Our technology will accelerate clean energy adoption by enabling rapid identification of natural hydrogen resources while maintaining superior environmental standards.” By enabling efficient and sustainable subsurface exploration, this study provides a blueprint for next-generation resource discovery, paving the way for large-scale clean energy infrastructure development.
About AIDEN DIGITAL LABS
AIDEN DIGITAL LABS is a global research and development firm specializing in the integration of information technology, nanotechnology, and sustainable solutions, focused on AI-powered tools and environmental innovations for energy and resource management.
About NANOGEIOS
NANOGEIOS is a global technology company headquartered in Miami, Florida, with research facilities in Osaka, Japan, and Paris, France. The company specializes in integrating nanotechnology, artificial intelligence, and advanced sensing to revolutionize resource identification and exploration through the IRIS-X platform.
Contact:
Media Relations: Helena Dilbar S.
Investor Relations: Professor Kazushi & AMS Serroune
Website: www.iris-exploration.com
Email: contact@aiden.ventures
Email: contact@nanogeios.io
Publication: IJCNIS
Publication: SSRN Elsevier
Publication: Valley International
Media Contact
Organization: GEIOS TECHNOLOGIES
Contact Person: Sandra Lebiewicz
Website: https://www.geios.net
Email: Send Email
Contact Number: +12396036828
Address:3401 N. MIAMI, AVE. STE 230
Address 2: Building B34-2nd Floor
City: MIAMI
State: FLORIDA
Country:United States
Release id:34272
The post NANOGEIOS Develops Revolutionary IRIS X Platform for Cost Effective Natural Hydrogen and Helium Detection appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
The Luxury Train Travel Company has announced a selection of featured luxury train journeys for 2025, showcasing extraordinary experiences across Europe, Asia, and Africa. Each journey combines timeless style, immersive itineraries, and five-star hospitality, offering travellers a unique way to explore the world by rail.
London, United Kingdom, 22nd Sep 2025 – Featured Luxury Train Journeys from The Luxury of Rail Travel in 2025
Luxury rail travel continues to grow in popularity as a stylish and sustainable alternative to flights and cruises. For 2025, The Luxury Train Travel Company is highlighting a collection of standout trains that reflect the best of this slow-travel trend. Each train offers cultural immersion, fine dining, and exceptional comfort while transporting guests through some of the world’s most captivating landscapes.
1. Rovos Rail Luxury Train – Africa: https://theluxurytraintravelcompany.com/trains/rovos-rail-luxury-train/
Dubbed the “Pride of Africa” Rovos Rail is one of the world’s most iconic luxury trains. From Cape Town to Victoria Falls it offers Edwardian-style carriages, world-class dining and African landscapes – from vineyards to savannahs
2. Danube Express Luxury Train – Europe: https://theluxurytraintravelcompany.com/trains/danube-express-luxury-train/
Known as the “Hotel on Wheels” the Danube Express offers refined service and panoramic views across Central and Eastern Europe. Budapest, Prague and Istanbul are on the itinerary, a seamless way to see some of Europe’s most beautiful cities in total comfort.
3. Al Andalus Luxury Train – Spain
Belle Époque charm meets modern comfort on the Al Andalus. Travel through the cultural heart of Andalusia with spacious suites, gourmet Spanish cuisine and stops in Seville, Córdoba and Granada. History, art and fine living on the rails.
4. Orient Silk Road Express – Central Asia
Follow in the footsteps of history’s great traders and explorers on this train that traverses the ancient Silk Road. Lavish interiors, expert guides and exclusive excursions make the Orient Silk Road Express a rare chance to connect with the cultural treasures of Uzbekistan, Kazakhstan and Turkmenistan.
From The Luxury Train Travel Company Founder
“Each journey tells a story,” said Chris Stanley, Founder of The Luxury Train Travel Company. “Our featured trains for 2025 are designed to inspire travellers who want something truly special in the year ahead.”
About The Luxury Train Travel Company
The Luxury Train Travel Company is a UK based, family run tour operator offering the world’s best rail journeys across Europe, Africa, Asia, Australasia and the Americas. Part of Headseast Ltd, the company has decades of experience in creating premium train holidays and a passion for rail travel as a way to see the world.
Media Contact
Organization: The Luxury Train Travel Company
Contact Person: Chris Stanley
Website: https://theluxurytraintravelcompany.com/
Email: Send Email
Contact Number: +02081910620
Address:9 Bonhill St
City: London
Country:United Kingdom
Release id:34237
The post The Luxury Train Travel Company Highlights Featured Luxury Train Journeys for 2025 appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
RMC MINING has long been a favorite among cryptocurrency enthusiasts for its ease of use and convenience. Unlike traditional mining, it requires no expensive hardware, specialized technology, or constant monitoring.
United Kingdom, 22nd Sep 2025 – In today’s financial landscape, Bitcoin remains a fascinating and often debated digital asset. A key factor behind its perceived value is scarcity. The total supply of Bitcoin is capped at 21 million, much like finite resources such as gold. From an economic standpoint, limited supply can create value, particularly when demand increases while the available quantity remains unchanged. As the difficulty of mining Bitcoin rises, the production rate slows down, reinforcing this scarcity over time.
Some analysts argue that this limited supply supports Bitcoin’s long-term value preservation, making it a potential hedge against inflation. However, it’s important to recognize that Bitcoin is not backed by tangible assets, unlike traditional financial instruments such as stocks or bonds. This lack of backing continues to raise questions about how investors can effectively manage risk when participating in the cryptocurrency space.
One alternative method for individuals interested in engaging with the Bitcoin ecosystem is through cloud mining. RMC MINING is a platform that offers access to cloud-based mining without requiring users to purchase or maintain hardware. This method allows users to rent computing power from remote data centers.
Overview of RMC MINING
RMC MINING is designed to simplify the mining process through a user-friendly interface that does not require advanced technical knowledge or equipment. Users can participate by choosing from various mining contracts that vary in cost, duration, and projected returns. The platform supports access to mining services powered by renewable energy sources and utilizes industry-standard ASIC and GPU hardware.
The platform reports that it operates over 50 mining farms globally and uses energy-efficient infrastructure to support environmental sustainability. It claims to prioritize transparency and user security, with most funds held in offline cold wallets and protected by security protocols such as McAfee® and Cloudflare®.
Key Platform Features
- Security Protocols: Most funds are stored offline and secured using industry-grade encryption and monitoring systems.
- Automated Transactions: Withdrawals are processed by the system in a timely manner.
- Green Energy Usage: Mining operations utilize renewable energy, supporting eco-friendly practices.
- Consistent Operations: The system is designed to provide predictable, stable performance during mining.
- Advanced Hardware: Incorporates the latest mining technology from companies such as Bitmain, Nvidia, and Canaan Creative.
- Technical Expertise: Operated by professionals from the blockchain and IT engineering fields.
Getting Started
To begin using the platform, individuals are required to register an account with a valid email address. Upon registration, users can explore available mining contracts. These contracts vary by investment amount and duration. Some are shorter-term options aimed at familiarizing users with the process, while others span several weeks and involve larger commitments.
This contract has a duration of 1 day. The estimated daily return is $0.63, and the total return at the end of the term is $18.63.
Short-Term Option:
With a duration of 2 days, this contract offers an estimated daily return of $5.00. By the end of the term, the total return amounts to $110.00.
Standard Contract:
This option lasts for 8 days and provides an estimated daily return of $12.80. At the end of the contract, the total return is $889.60.
Long-Term Contract:
The longest of the options, this contract runs for 31 days. It offers a significant estimated daily return of $18,500.00, resulting in a total return of $1,073,500.00 by the end of the term.
Conclusion
Bitcoin’s scarcity-driven value continues to attract attention, and cloud mining presents one way for individuals to engage in this evolving space. Platforms such as RMC MINING provide access to mining infrastructure without the need for hardware ownership. As with any financial activity, potential users should approach opportunities with care, verify claims, and ensure they understand the risks involved.
For more details, visit the official website: https://rmcmining.com
Media Contact
Organization: RMC Holdings Ltd
Contact Person: Smith Ethan
Website: https://rmcmining.com/
Email: Send Email
Address:Ballyscandal Road, Armagh, Northern Ireland
Country:United Kingdom
Release id:34203
Disclaimer: This press release is for informational purposes only and does not constitute investment advice. Cryptocurrency investments, including cloud mining, carry inherent risks. Readers should conduct their own research and consult with a qualified financial advisor before making any investment decisions.
The post Understanding Bitcoin Scarcity and an Overview of RMC MININGs Cloud Mining Platform appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
China Medical System (867.HK; 8A8.SG) Signed Collaboration Agreements for Two Innovative Biologics Used for Passive Immunization Against Tetanus and Rabies
NANOGEIOS Develops Revolutionary IRIS X Platform for Cost Effective Natural Hydrogen and Helium Detection
The Luxury Train Travel Company Highlights Featured Luxury Train Journeys for 2025
Bay Smokes Maintains Quality Amid Legislative Changes in the Hemp Industry
Microsoft License Enables Organizations to Navigate the Evolving Digital Landscape Through Customized Microsoft Solutions
Benzinga Money Article Discusses How to Become Part of the 12% of Retirees Who Have Achieved the Recommended $550,000 Minimum Retirement Savings Threshold
-
Press Release5 days ago
The Rooter Guys LLC Introduces Advanced Hydro-Jetting Technology for Superior Drain Cleaning in Colorado Springs
-
Press Release1 week ago
Software Applications Launches All-in-One Business Management Platform to Simplify Operations for Businesses of All Sizes
-
Press Release7 days ago
DTF Printing Expands Operations in Dallas to Showcase Advanced Direct-to-Film Technology for Growing $44 Billion Custom Apparel Market
-
Press Release3 days ago
AA Biotek and Philippine Carabao Center Forge Strategic MOA to Advance Sustainable Livestock and Agricultural Biotechnology in Nueva Ecija Philippines
-
Press Release4 days ago
Rankiteo Now Owns and Maintains the Worlds Global Cybersecurity Incident Database Transforming the Future of Cyber Insurance
-
Press Release1 week ago
DTF CENTER Expands Market Reach with Premium DTF Transfers and Gang Sheets
-
Press Release1 week ago
STACO Network Unveils Next-Generation Web3 Protocol for Interoperable Oracles
-
Press Release1 week ago
Unseen Path Memoir Unlocks AI-Powered Passive Millions The Solo-Preneurs Definitive Guide to a New Era of Wealth